Thursday, February 2, 2023

The United States authorized a new and long-awaited treatment against Alzheimer’s

federal regulatory agency for food and drugs of the United States FDAofficial this friday a new drug highly anticipated against alzheimer’sThis is intended to reduce cognitive decline in patients suffering from neurodegenerative diseases.

The new treatment, which will be marketed by pharmaceutical company Eisai under the name Leqembi, is recommended by the FDA for patients who have not yet reached an advanced stage of the disease.

The drug represents “an important step in our fight to effectively treat Alzheimer’s disease,” which affects an estimated 6.5 million Americans, the FDA said in a statement.

Lecanbi, whose active substance is called lecanumab, attacks deposits of a protein called beta-amyloid.

Although the cause of Alzheimer’s disease is not well understood, patients develop amyloid plaques in the brain, which build up around neurons and eventually destroy them. This causes the memory loss characteristic of the disease.

The FDA’s approval is based on clinical trial results showing the drug helped reduce amyloid plaques.

In addition, the agency cites results from large clinical trials recently published in a scientific journal.

In these studies of nearly 1,800 people who were followed for 18 months, cognitive decline was reduced by 27% in patients treated with lecanumab.

But clinical trials also showed serious adverse effects: Some treated patients suffered brain hemorrhages.

Additionally, at least one person who received the treatment died. The FDA included a warning about the risk of bleeding in the drug information.

It is the second recent FDA-approved Alzheimer’s treatment due in June 2021, after EduHelm (which uses a molecule called aducanumab).

But the launch of Adhelm was not as successful as expected. Its authorization sparked controversy, as some experts criticized the lack of evidence on its effectiveness. Later, its use was restricted to people with moderate cases of the disease.

A recent report by the US House of Representatives also criticized the exorbitant price of Adhelmin ($56,000 per year), and Medicare, the federal health care system for the elderly, announced that it would only reimburse it in clinical trials.

AFP

Nation World News Desk
Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news